Filter By Category
Archives
Share on -
DUVELISIB
Generic Name: DUVELISIB
ABSTRACT -
Duvelisib is an oral PI3K-delta/gamma inhibitor approved for selected relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after prior therapies.
DOSAGE -
Oral 25 mg twice daily is a standard adult regimen for approved use; follow current prescribing information for dose modifications and indications.
SIDE EEFECTS -
- Diarrhea or colitis
- Neutropenia
- Rash
- Fatigue
- Elevated liver enzymes or infection
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or urticaria
- Severe cutaneous reaction
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Strong CYP3A inhibitors may increase duvelisib exposure
- Strong CYP3A inducers may reduce exposure
- Avoid live vaccines and monitor interactions with immunosuppressants
PREAUTONS–
- Pneumocystis jirovecii prophylaxis is recommended during treatment
- Monitor for infections, diarrhea/colitis, pneumonitis, liver toxicity, and neutropenia
- Use antiviral prophylaxis per label guidance
WARNINGS –
- Boxed warnings include fatal/serious infections, diarrhea/colitis, cutaneous reactions, and pneumonitis
- Treatment requires careful monitoring and dose interruption/discontinuation rules
Share on -
. Developed by